Bank Of New York Mellon Corp Lyell Immunopharma, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$2.78 - $8.09 $1.82 Million - $5.31 Million	656,210 New	656,210 $2.28 Million
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $606,602 - $905,523	109,495 Added 19.93%	658,756 $4.83 Million
Q2 2022 Aug 15, 2022	BUY	$3.68 - $6.8 $585,469 - $1.08 Million	159,095 Added 40.78%	549,261 $3.58 Million
Q1 2022 May 11, 2022	BUY	$5.05 - $7.7 $1.61 Million - $2.46 Million	318,890 Added 447.4%	390,166 $1.97 Million
Q4 2021 Feb 11, 2022	BUY	$7.13 - $15.19 $90,251 - $192,275	12,658 Added 21.59%	71,276 $552,000
Q3 2021 Nov 12, 2021	BUY	$11.0 - $17.95 $644,798 - $1.05 Million	58,618 New	58,618 $867,000

121

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.